ArticleFrontiers in oncology2025
Case Report: Renal metastasis of a gastric gastrointestinal stromal tumor mimicking a primary renal carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastrointestinal stromal tumors (GISTs), mesenchymal neoplasms of the gastrointestinal tract, are prone to recurrence and metastasis. Despite improvements in prognosis with targeted treatments, such as imatinib, some patients develop metastatic GIST. Renal involvement in GIST is uncommon, and data on the diagnosis and treatment of GIST with renal metastasis remain limited. In this report, we describe the diagnostic and therapeutic regimen used for a patient with renal metastasis from GIST, providing an important reference for clinicians. Case presentation: A 52-year-old man underwent resection of a gastric GIST 5 years previously and had received adjuvant imatinib therapy for 2 years. A radical nephrectomy was performed, and histopathological analysis confirmed metastatic GIST. Although the patient resumed imatinib therapy post-surgery, follow-up imaging 22 months later revealed multiple metastases in the retroperitoneum and abdominal cavity. Conclusion: Renal metastasis from GIST is highly aggressive. Although surgical resection offers considerable palliation and may prolong survival, survival is generally dependent on sustained multimodal therapy and follow-up. Early detection and management of recurrent or metastatic lesions are imperative to optimize long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.